



(12) Translation of
European patent specification

(11) NO/EP 2909232 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 14/47 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.07.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.03.11
(86)	European Application Nr.	13777084.8
(86)	European Filing Date	2013.10.17
(87)	The European Application's Publication Date	2015.08.26
(30)	Priority	2012.10.17, EP, 12306278
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Institut National de la Santé et de la Recherche Médicale (INSERM), 101, rue de Tolbiac, 75013 Paris, Frankrike Centre National de la Recherche Scientifique (C.N.R.S.), 3, rue Michel-Ange, 75016 Paris, Frankrike
(72)	Inventor	LEVEILLARD, Thierry, Institut de la Vision UMR-S 96817 rue Moreau, F-75012 Paris, Frankrike SAHEL, José-Alain, Institut de la Vision UMR-S 96817 rue Moreau, F-75012 Paris, Frankrike CRONIN, Thérèse, Neural Circuits Roska LaboratoryMaulbeestrasse 66P.O. Box 3775, 4002 Basel, Sveits BYRNE, Leah, Schaffer Lab/Helen Wills Neuroscience Institute278 Stanley Hall, Berkeley, CA 94720, USA FRIDLICH, Ram, Département de GénétiqueInstitut de la Vision UMR-S968Université Pierre et Marie CurieINSERM - CNRS17 rue Moreau, 75012 Paris, Frankrike
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)**

(56) References Cited: WO-A2-2005/113586
 WO-A2-02/081513
 EP-A1- 2 383 286
 WO-A2-2013/063383
 THIERRY LÉVEILLARD ET AL: "Rod-Derived Cone Viability Factor for Treating Blinding

Diseases: From Clinic to Redox Signaling", SCIENCE TRANSLATION MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 2, no. 26, 7 April 2010 (2010-04-07), pages 1-5, XP009160751, ISSN: 1946-6234, DOI: 10.1126/SCITRANSLMED.3000866

Leah C Byrne ET AL: "AAV-Mediated Delivery of RdCVF and RdCVFL in a Mouse Model of Retinal Degeneration", ARVO 2012 Annual Meeting Abstracts:45 PM -3:30 PM Hall B/C Poster Session Program Program Number: 1907 Poster Board Number: D724, 7 May 2012 (2012-05-07), XP055089097, Retrieved from the Internet: URL:<http://www.eyes.org.il/Lirot/SendFile.asp?DBID=1&LNGID=2&GID=899> [retrieved on 2013-11-19]

T CRONIN ET AL: "The disruption of the rod-derived cone viability gene leads to photoreceptor dysfunction and susceptibility to oxidative stress", CELL DEATH AND DIFFERENTIATION, vol. 17, no. 7, 5 February 2010 (2010-02-05), pages 1199-1210, XP055045992, ISSN: 1350-9047, DOI: 10.1038/cdd.2010.2

BYRNE LEAH C ET AL: "AAV-mediated Delivery of Rod-derived Cone Viability Factor in a Mouse Model of Retinal Degeneration", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2011, May 2011 (2011-05), page 1395, XP002716687, & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPTHALMOLOGY (ARVO); FT LAUDERDALE, FL, USA; MAY 01 -05, 2011

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Et stangavledet Cone Viability Factor Long isoform (RdCVFL) polynukleotid eller polypeptid for bruk i en metode for behandling av aldersrelatert makulær degenerasjon (AMD) i et individ som trenger dette, ved å redusere malondialdehyd (MDA) nivået i netthinnen.
5
2. RdCVFL-polynukleotid for anvendelse ifølge krav 1, hvor RdCVFL polynukleotidsekvensen er assosiert med elementer som muliggjør regulering av dens ekspresjon.
10
3. RdCVFL-polynukleotid for anvendelse ifølge krav 2, hvor elementene som muliggjør regulering av dets ekspresjon omfatter en promotorsekvens.
- 15 4. RdCVFL-polynukleotid for anvendelse ifølge krav 1, hvor RdCVFL polynukleotidsekvensen er i form av en vektor.
5. RdCVFL-polynukleotid for anvendelse ifølge krav 4, hvor vektoren er en AAV-vektor.
- 20 6. RdCVFL-polynukleotid eller polypeptid for anvendelse ifølge krav 1, hvor RdCVFL-polynukleotid eller polypeptid blir levert i en farmasøytisk akseptabel oftalmisk bærer.